Check out the top 5 interviews from SLEEP 2025.
Danny Eckert, PhD
Advertisement
Articles by Danny Eckert, PhD
At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5